Treating tyoe 1 and 2 diabetes Flashcards
what is the by-product of insulin?
C-peptide
can be used as a biomarker
what is the treatment for type 1 diabetes?
insulin injections
what are the types of insulin?
rapid, short, intermediate or long acting
biphasic insulin preparations
rapid acting insulin
acts for 2 hours
e.g. aspart lispro and glulisine
short acting insulin
acts for 6 hours
regular/soluble insulin
intermediate acting insulin
acts for 18 hours
NPH/isophane insulin
long acting insulin
acts for 20-24 hours
glargine or detemir
biphasic preparations
mixture of short/ rapid acting and intermediate acting insulin
regular human insulin
forms hexamers around zinc ions which slows absorption
how to make different preparations of insulin
insulin analogues with different durations of actions can be made by modifying regular insulin using recombinant technology
what are the most common regimens for type 1 diabetes?
twice daily regiment
basal-bolus regimen
twice daily regimen
injecting a mixture of shorter acting insulin and intermediate acting insulin twice - biphasic preparation twice a day
injected before breakfast and dinner
basal bolus regimen
long-acting insulin delivered 1 or 2 times a day with a rapid-acting insulin administered before meals
requires need for carbohydrate counting
how is insulin delivered?
subcutaneous injection by patient/carer
which insulin regimen is used for school children with T1DM?
biphasic twice daily regimen
as can be administered at home
other insulin administration techniques
insulin pump
insulin pump
delivers basal flow of insulin throughout day
bolus delivered before meals
requires counting and inputting of carbohydrate intake
closed loop systems
ongoing development
it automatically reads blood glucose and releases appropriate amount of insulin
alternative treatment options for type 1 diabetes
isolated islet or whole organ - pancreatic transplant
islet transplantation
injection of isolated islets into portal vein
islets do endocrine job of pancreas in the liver
who is considered for pancreatic transplant?
those who experience episodes of unexpected dangerously low blood sugar levels despite good insulin control
those with severe kidney disease
what are the core defects of type 2 diabetes?
ominous octet
ominous octet
increased hepatic glucose production decreased glucose uptake increased lipolysis decreased incretin effect increased glucagon secretion increased glucose reabsorption by kidney neurotransmitter dysfunction decreased insulin secretion
what are the treatment options for type 2 diabetes?
lifestyle changes - diet and exercise, weight loss, smoking cessation and reduced alcohol intake
oral medications
insulin
oral medications for T2DM
metformin GLP-1 agonists DPP-4 inihibitors sulphonylureas thiazolidinediones alpha-glucosidase inhibitors SGLT2 inhibitors
metformin target organs
liver
intestines
kidneys
peripheral cells
how does metformin work?
decreases intestinal absorption of glucose
increases peripheral glucose uptake and utilisation
decreases hepatic glucose production - increases insulin sensitivity of liver
affects mitochondrial activity
GLP-1 agonist target organs
brain
gut
pancreatic islets
how do GLP-1 agonists work?
block inactivation of incretin hormones - GLP-1 leading to higher levels of incretins so there is increased insulin secretion
can help weight loss and reduce appetite
DPP-4 inhibitors target organs
fat
pancreas
liver
kidneys
how does DPP-4 inhibitors work?
increase efficacy of GLP-1 by reducing the breakdown of it
what organs do sulphonylureas target?
pancreas
sulphonylureas mode of action
induce insulin secretion by beta cells by blocking potassium ion channels which depolarises the cells and causes influx of calcium ions which causes vesicles containing insulin to release the insulin
what are the target organs of thiazolidinediones?
adipose tissues
other peripheral tissues
how do thiazolidinediones work?
increases lipogenesis enhances fatty acid and glucose uptake promotes sodium reabsorption in collecting ducts promotes insulin sensitivity can cause weight gain
target organs of alpha-glucosidase inhibitors
small intestines
target organs for SSGLT2 inhibitors
kidneys
mode of action of alpha-glucosidase inhibitors
inhibit hydrolysis of complex carbohydrates in the small intestines
mode of action of SSGLT2 inhibitors
inhibit reabsorption of glucose in PCT so there is an increase in urinary glucose excretion